Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study

ConclusionsThe safety profile of cobimetinib in pediatrics was similar to that reported in adults. Clinical activity was observed in LGG patients with known/suspected MAPK pathway activation. Cobimetinib combination regimens may be required to improve response rates in this pediatric population.Clinical Trial RegistrationClinicalTrials.gov NCT02639546, registered December 24, 2015.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research